https://www.selleckchem.com/products/nb-598.html
During 1-year follow-up, 1445 diagnoses of opioid use disorder or opioid poisoning occurred in the ADF oxycodone cohort (34.8/1000 person-years) and 765 occurred in the non-ADF oxycodone cohort (18.2/1000 person-years). The odds of opioid-related adverse outcomes were increased in the ADF oxycodone cohort compared with the non-ADF oxycodone opioid cohort, including for opioid use disorders (OR=2.02; 95% CI=1.83, 2.23) and opioid poisoning (OR=1.64 95% CI=1.35, 1.99). Patients with a new prescription of abuse-deterrent formulation oxycodo